HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Stephen G. Swisher Jack A. Roth Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agarwal, B. Articles by Roth, J. A. Search for Related Content PubMed PubMed Citation Articles by Agarwal, B. Articles by Roth, J. A. Related Collections Esophagus - cancer

Ann Thorac Surg 2005;79:1716-1723
© 2005 The Society of Thoracic Surgeons

---

Original articles: General thoracic

Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic Gastroesophageal Reflux

^a Department of Gastrointestinal Medicine and Nutrition, M. D. Anderson Cancer Center, Houston, Texas
^b Department of Medical Oncology, M. D. Anderson Cancer Center, Houston, Texas
^c Department of Radiation Oncology, M. D. Anderson Cancer Center, Houston, Texas
^d Department of Thoracic and Cardiovascular Surgery, M. D. Anderson Cancer Center, Houston, Texas

Accepted for publication October 18, 2004.

^_* Address reprint requests to Dr Agarwal, Therapeutic Endoscopy Division of Gastroenterology and Hepatology, St. Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110 (E-mail: agarwalb{at}slu.edu).

BACKGROUND: Barrett's esophagus and gastroesophageal reflux disease (GERD) are recognized to predispose to esophageal adenocarcinoma. Abdel-Latif and colleagues recently suggested that esophageal adenocarcinoma patients with GERD might be resistant to multimodality treatment. In this study, we investigated potential differences in clinical outcomes in esophageal adenocarcinoma patients based on the presence of identifiable Barrett's mucosa and/or history of symptomatic GERD.

METHODS: Eighty-four patients with resectable esophageal adenocarcinoma, who completed the planned preoperative chemoradiation and underwent a potentially curative esophageal resection were retrospectively evaluated. Postoperative survival was compared between patients with or without underlying Barrett's esophagus and history of symptomatic GERD. Patients with pathologic complete response (path CR) and those with partial or no response (path PR) were compared to determine if presence of Barrett's esophagus and history of symptomatic GERD influence the path CR rates.

RESULTS: We found significantly lower postoperative survival in patients with Barrett's associated adenocarcinoma (vs adenocarcinoma arising de novo, p = 0.031) and patients with symptomatic GERD (vs patients without symptomatic GERD, p = 0.019). Furthermore, the subset of patients with path PR (vs path CR) after chemoradiation have a significantly higher proportion of patients with Barrett's esophagus (HR = 4.38, confidence interval [CI] = 1.39 to 13.83, p = 0.012) and patients with GERD (HR = 2.71, CI = 1.13 to 6.50, p = 0.026).

CONCLUSIONS: Patients with esophageal adenocarcinoma may have differences in response to preoperative chemoradiation based on the presence of Barrett's esophagus and history of symptomatic GERD.

This article has been cited by other articles:

				M. G. Luthra, J. A. Ajani, J. Izzo, J. Ensor, T.-T. Wu, A. Rashid, L. Zhang, A. Phan, N. Fukami, and R. Luthra Decreased Expression of Gene Cluster at Chromosome 1q21 Defines Molecular Subgroups of Chemoradiotherapy Response in Esophageal Cancers Clin. Cancer Res., February 1, 2007; 13(3): 912 - 919. [Abstract] [Full Text] [PDF]